Sensitive  ||| S:0 E:10 ||| JJ
immunochemical  ||| S:10 E:25 ||| JJ
approaches  ||| S:25 E:36 ||| NNS
for  ||| S:36 E:40 ||| IN
quantitative  ||| S:40 E:53 ||| JJ
( ||| S:53 E:54 ||| -LRB-
FPIA ||| S:54 E:58 ||| NNP
)  ||| S:58 E:60 ||| -RRB-
and  ||| S:60 E:64 ||| CC
qualitative  ||| S:64 E:76 ||| NNS
( ||| S:76 E:77 ||| -LRB-
lateral  ||| S:77 E:85 ||| JJ
flow  ||| S:85 E:90 ||| NN
tests ||| S:90 E:95 ||| NNS
)  ||| S:95 E:97 ||| -RRB-
determination  ||| S:97 E:111 ||| NN
of  ||| S:111 E:114 ||| IN
gentamicin  ||| S:114 E:125 ||| NN
in  ||| S:125 E:128 ||| IN
milk  ||| S:128 E:133 ||| NN
Three  ||| S:133 E:139 ||| CD
kinds  ||| S:139 E:145 ||| NNS
of  ||| S:145 E:148 ||| IN
immunoassays  ||| S:148 E:161 ||| NN
for  ||| S:161 E:165 ||| IN
the  ||| S:165 E:169 ||| DT
determination  ||| S:169 E:183 ||| NN
of  ||| S:183 E:186 ||| IN
gentamicin  ||| S:186 E:197 ||| NN
in  ||| S:197 E:200 ||| IN
milk  ||| S:200 E:205 ||| NN
samples  ||| S:205 E:213 ||| NNS
were  ||| S:213 E:218 ||| VBD
developed  ||| S:218 E:228 ||| VBN
and  ||| S:228 E:232 ||| CC
validated ||| S:232 E:241 ||| NN
.  ||| S:241 E:243 ||| .
First ||| S:243 E:248 ||| NNP
,  ||| S:248 E:250 ||| ,
a  ||| S:250 E:252 ||| DT
fast  ||| S:252 E:257 ||| JJ
and  ||| S:257 E:261 ||| CC
easily-performed  ||| S:261 E:278 ||| JJ
fluorescence  ||| S:278 E:291 ||| JJ
polarization  ||| S:291 E:304 ||| JJ
immunoassay  ||| S:304 E:316 ||| NN
was  ||| S:316 E:320 ||| VBD
used  ||| S:320 E:325 ||| VBN
for  ||| S:325 E:329 ||| IN
characterization  ||| S:329 E:346 ||| NN
of  ||| S:346 E:349 ||| IN
the  ||| S:349 E:353 ||| DT
employed  ||| S:353 E:362 ||| VBN
polyclonal  ||| S:362 E:373 ||| JJ
antibody ||| S:373 E:381 ||| NN
.  ||| S:381 E:383 ||| .
The  ||| S:383 E:387 ||| DT
calculated  ||| S:387 E:398 ||| JJ
Kaff  ||| S:398 E:403 ||| NNP
were  ||| S:403 E:408 ||| VBD
( ||| S:408 E:409 ||| -LRB-
1.9±0.4 ||| S:409 E:416 ||| NNP
) ||| S:416 E:417 ||| -RRB-
×10 ||| S:417 E:420 ||| NNP
( ||| S:420 E:421 ||| -LRB-
9 ||| S:421 E:422 ||| CD
) ||| S:422 E:423 ||| -RRB-
М ||| S:423 E:424 ||| NNP
( ||| S:424 E:425 ||| -LRB-
-1 ||| S:425 E:427 ||| NNP
)  ||| S:427 E:429 ||| -RRB-
and  ||| S:429 E:433 ||| CC
( ||| S:433 E:434 ||| -LRB-
6.0±0.2 ||| S:434 E:441 ||| NNP
) ||| S:441 E:442 ||| -RRB-
×10 ||| S:442 E:445 ||| NNP
( ||| S:445 E:446 ||| -LRB-
6 ||| S:446 E:447 ||| CD
) ||| S:447 E:448 ||| -RRB-
М ||| S:448 E:449 ||| NNP
( ||| S:449 E:450 ||| -LRB-
-1 ||| S:450 E:452 ||| NNP
)  ||| S:452 E:454 ||| -RRB-
for  ||| S:454 E:458 ||| IN
the  ||| S:458 E:462 ||| DT
high-  ||| S:462 E:468 ||| JJ
and  ||| S:468 E:472 ||| CC
low-affinity  ||| S:472 E:485 ||| JJ
fractions  ||| S:485 E:495 ||| NNS
respectively ||| S:495 E:507 ||| RB
.  ||| S:507 E:509 ||| .
The  ||| S:509 E:513 ||| DT
assay  ||| S:513 E:519 ||| NN
was  ||| S:519 E:523 ||| VBD
characterized  ||| S:523 E:537 ||| VBN
with  ||| S:537 E:542 ||| IN
a  ||| S:542 E:544 ||| DT
good  ||| S:544 E:549 ||| JJ
sensitivity ||| S:549 E:560 ||| NN
,  ||| S:560 E:562 ||| ,
the  ||| S:562 E:566 ||| DT
limit  ||| S:566 E:572 ||| NN
of  ||| S:572 E:575 ||| IN
detection  ||| S:575 E:585 ||| NNS
being  ||| S:585 E:591 ||| VBG
5μgkg ||| S:591 E:596 ||| NNP
( ||| S:596 E:597 ||| -LRB-
-1 ||| S:597 E:599 ||| NNP
) ||| S:599 E:600 ||| -RRB-
.  ||| S:600 E:602 ||| .
Two  ||| S:602 E:606 ||| CD
different  ||| S:606 E:616 ||| JJ
kinds  ||| S:616 E:622 ||| NNS
of  ||| S:622 E:625 ||| IN
detection  ||| S:625 E:635 ||| JJ
labels ||| S:635 E:641 ||| NNS
,  ||| S:641 E:643 ||| ,
i.e.  ||| S:643 E:648 ||| FW
colloidal  ||| S:648 E:658 ||| FW
gold  ||| S:658 E:663 ||| FW
( ||| S:663 E:664 ||| -LRB-
CG ||| S:664 E:666 ||| NNP
)  ||| S:666 E:668 ||| -RRB-
and  ||| S:668 E:672 ||| CC
quantum  ||| S:672 E:680 ||| JJ
dots  ||| S:680 E:685 ||| NNS
( ||| S:685 E:686 ||| -LRB-
QDs ||| S:686 E:689 ||| NNP
) ||| S:689 E:690 ||| -RRB-
,  ||| S:690 E:692 ||| ,
were  ||| S:692 E:697 ||| VBD
evaluated  ||| S:697 E:707 ||| VBN
for  ||| S:707 E:711 ||| IN
use  ||| S:711 E:715 ||| NN
in  ||| S:715 E:718 ||| IN
lateral-flow  ||| S:718 E:731 ||| JJ
format  ||| S:731 E:738 ||| NN
with  ||| S:738 E:743 ||| IN
respect  ||| S:743 E:751 ||| NN
to  ||| S:751 E:754 ||| TO
rapid  ||| S:754 E:760 ||| JJ
visual  ||| S:760 E:767 ||| JJ
on-site  ||| S:767 E:775 ||| JJ
testing ||| S:775 E:782 ||| NN
.  ||| S:782 E:784 ||| .
The  ||| S:784 E:788 ||| DT
cut-off  ||| S:788 E:796 ||| JJ
levels  ||| S:796 E:803 ||| NNS
for  ||| S:803 E:807 ||| IN
both  ||| S:807 E:812 ||| DT
qualitative  ||| S:812 E:824 ||| JJ
formats  ||| S:824 E:832 ||| NNS
were  ||| S:832 E:837 ||| VBD
selected  ||| S:837 E:846 ||| VBN
based  ||| S:846 E:852 ||| VBN
on  ||| S:852 E:855 ||| IN
the  ||| S:855 E:859 ||| DT
maximum  ||| S:859 E:867 ||| JJ
level  ||| S:867 E:873 ||| NN
for  ||| S:873 E:877 ||| IN
gentamicin  ||| S:877 E:888 ||| NN
in  ||| S:888 E:891 ||| IN
milk  ||| S:891 E:896 ||| NN
established  ||| S:896 E:908 ||| VBN
by  ||| S:908 E:911 ||| IN
the  ||| S:911 E:915 ||| DT
European  ||| S:915 E:924 ||| NNP
Commission ||| S:924 E:934 ||| NNP
,  ||| S:934 E:936 ||| ,
100μgkg ||| S:936 E:943 ||| NNP
( ||| S:943 E:944 ||| -LRB-
-1 ||| S:944 E:946 ||| NNP
) ||| S:946 E:947 ||| -RRB-
,  ||| S:947 E:949 ||| ,
resulting  ||| S:949 E:959 ||| VBG
in  ||| S:959 E:962 ||| IN
a  ||| S:962 E:964 ||| DT
10μgkg ||| S:964 E:970 ||| NNP
( ||| S:970 E:971 ||| -LRB-
-1 ||| S:971 E:973 ||| NNP
)  ||| S:973 E:975 ||| -RRB-
cut-off  ||| S:975 E:983 ||| JJ
considering  ||| S:983 E:995 ||| VBG
sample  ||| S:995 E:1002 ||| NN
dilution ||| S:1002 E:1010 ||| NN
.  ||| S:1010 E:1012 ||| .
The  ||| S:1012 E:1016 ||| DT
intra-laboratory  ||| S:1016 E:1033 ||| JJ
validation  ||| S:1033 E:1044 ||| NN
was  ||| S:1044 E:1048 ||| VBD
performed  ||| S:1048 E:1058 ||| VBN
with  ||| S:1058 E:1063 ||| IN
sterilized  ||| S:1063 E:1074 ||| JJ
milk  ||| S:1074 E:1079 ||| NN
samples  ||| S:1079 E:1087 ||| NNS
artificially  ||| S:1087 E:1100 ||| RB
spiked  ||| S:1100 E:1107 ||| VBN
with  ||| S:1107 E:1112 ||| IN
gentamicin  ||| S:1112 E:1123 ||| NN
at  ||| S:1123 E:1126 ||| IN
concentrations  ||| S:1126 E:1141 ||| NNS
less  ||| S:1141 E:1146 ||| RBR
than ||| S:1146 E:1150 ||| IN
,  ||| S:1150 E:1152 ||| ,
equal  ||| S:1152 E:1158 ||| JJ
to ||| S:1158 E:1160 ||| TO
,  ||| S:1160 E:1162 ||| ,
and  ||| S:1162 E:1166 ||| CC
greater  ||| S:1166 E:1174 ||| JJR
than  ||| S:1174 E:1179 ||| IN
the  ||| S:1179 E:1183 ||| DT
cut-off  ||| S:1183 E:1191 ||| JJ
level ||| S:1191 E:1196 ||| NN
.  ||| S:1196 E:1198 ||| .
It  ||| S:1198 E:1201 ||| PRP
was  ||| S:1201 E:1205 ||| VBD
shown  ||| S:1205 E:1211 ||| VBN
that  ||| S:1211 E:1216 ||| IN
milk  ||| S:1216 E:1221 ||| NN
products  ||| S:1221 E:1230 ||| NNS
could  ||| S:1230 E:1236 ||| MD
be  ||| S:1236 E:1239 ||| VB
analyzed  ||| S:1239 E:1248 ||| VBN
without  ||| S:1248 E:1256 ||| IN
any  ||| S:1256 E:1260 ||| DT
sample  ||| S:1260 E:1267 ||| NN
preparation ||| S:1267 E:1278 ||| NN
,  ||| S:1278 E:1280 ||| ,
except  ||| S:1280 E:1287 ||| IN
for  ||| S:1287 E:1291 ||| IN
dilution  ||| S:1291 E:1300 ||| NN
with  ||| S:1300 E:1305 ||| IN
the  ||| S:1305 E:1309 ||| DT
buffer  ||| S:1309 E:1316 ||| NN
solution ||| S:1316 E:1324 ||| NN
.  ||| S:1324 E:1326 ||| .
The  ||| S:1326 E:1330 ||| DT
rates  ||| S:1330 E:1336 ||| NNS
of  ||| S:1336 E:1339 ||| IN
false-positive  ||| S:1339 E:1354 ||| JJ
and  ||| S:1354 E:1358 ||| CC
false-negative  ||| S:1358 E:1373 ||| JJ
results  ||| S:1373 E:1381 ||| NNS
were  ||| S:1381 E:1386 ||| VBD
below  ||| S:1386 E:1392 ||| IN
5 ||| S:1392 E:1393 ||| CD
%  ||| S:1393 E:1395 ||| NN
for  ||| S:1395 E:1399 ||| IN
both  ||| S:1399 E:1404 ||| DT
labels ||| S:1404 E:1410 ||| NNS
.  ||| S:1410 E:1412 ||| .
The  ||| S:1412 E:1416 ||| DT
different  ||| S:1416 E:1426 ||| JJ
developed  ||| S:1426 E:1436 ||| JJ
immunoassays  ||| S:1436 E:1449 ||| NN
were  ||| S:1449 E:1454 ||| VBD
tested  ||| S:1454 E:1461 ||| VBN
towards  ||| S:1461 E:1469 ||| IN
gentamicin  ||| S:1469 E:1480 ||| JJ
determination  ||| S:1480 E:1494 ||| NN
in  ||| S:1494 E:1497 ||| IN
artificially-spiked  ||| S:1497 E:1517 ||| JJ
and  ||| S:1517 E:1521 ||| CC
naturally  ||| S:1521 E:1531 ||| RB
contaminated  ||| S:1531 E:1544 ||| VBN
milk  ||| S:1544 E:1549 ||| NN
samples ||| S:1549 E:1556 ||| NNS
.  ||| S:1556 E:1558 ||| .
